I kliniske studier, inden for alle indikationer, var hyppigheden af venøse tromboemboliske hændelser mellem 2, 8% til 17, 3% af de Avastinbehandlede patienter i forhold til 3, 2% - 15, 6% i kontrolgrupperne.
In clinical trials across indications, the overall incidence of venous thromboembolic events ranged from 2.8% to 17.3% of Avastin-treated patients compared with 3.2% to 15.6% in the control arms.